Consistent with the cardiac dysfunction in the AngII group, the expression of ANP and BNP, markers of hypertrophic cardiomyopathy, was upregulated, which was also alleviated by DNJ treatment (Figure 12D and Supplemental Figure 14, A and B). Here, NPPB is linked to hypertrophic cardiomyopathy.